The Top 5 Biosimilars Articles for the Year 2019

December 27, 2019

The Center for Biosimilars® recaps the top stories for the year 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the year 2019.

Number 5: In January, Pfizer confirmed that it made the decision to terminate 5 preclinical biosimilar programs after the results of the company’s annual investment review.

Number 4: Also in January, the FDA approved Samsung Bioepis’ Ontruzant, a biosimilar trastuzumab referencing Herceptin.

Number 3: In August, UnitedHealthcare indicated that it would prefer 2 oncology biosimilars in its commercial and community plans.

Number 2: In May, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.

Number 1: Finally, the US market got its first anticancer biosimilars in July when Amgen and Allergan launched biosimilar bevacizumab and trastuzumab.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Business | Regulatory

x